Recent Patents on Endocrine, Metabolic and Immune Drug Discovery This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Current updates in the medical management of obesity.
Authors: Khan A, Raza S, Khan Y, Aksoy T, Khan M, Weinberger Y, Goldman J Abstract Obesity is a chronic medical condition that is expected to become an indirect but leading cause of mortality and morbidity. Obesity results in type 2 diabetes mellitus, insulin resistance, hypertension, dyslipidemia, coronary heart disease. These factors contribute to cardiovascular disease that is a leading cause of death. Therefore, the approach to obesity therapy should be designed to reduce cardiovascular disease risk and mortality. Diet and lifestyle changes remain the cornerstones of therapy for obesity, but the result...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus.
Authors: Baruah MP, Kalra S Abstract Type 2 diabetes mellitus (T2DM) is a global public health problem. Due to the progressive nature of the disease, a combination(s) of two or more drugs acting on different pathophysiological process is often necessary to achieve early and sustained achievement of individualized glycemic targets. At the same time, choosing the safest option to avoid hypoglycemia is of paramount importance. GLP-1 analogues are a relatively recent class of anti-diabetic drugs, and are highly effective with an acceptable safety profile. Attempts have been made to combine GLP-1 analogues with...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis.
Authors: Pasqualetti G, Ricci S, Boni G, Tognini S, Polini A, Mariani G, Ferdeghini M, Monzani F Abstract Tyrosine kinase receptors play an important role in tumor angiogenesis and, their implication in epithelial thyroid tumor growth has been highlighted. Sunitinib is a novel tyrosine kinase inhibitor, approved in 2006 by Food and Drug Administration for the treatment of advanced renal cell and gastrointestinal stromal tumors. Preliminary promising results have been also obtained in patients with RAI-resistant thyroid neoplasia. In the current study, our experience on 9 patients with advanced thyroid epit...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Potential role of Rho-associated protein kinase inhibitors for glaucoma treatment.
Authors: Colligris B, Crooke A, Huete F, Pintor J Abstract Rho kinase inhibitors are widely considered as a new treatment for glaucoma. Rho kinase inhibition has been shown in vitro and in vivo to lower intraocular pressure. Furthermore in the first clinical reports involving healthy human subjects, the results were quite promising. The potential of this new class of medicines is enormous in a field where there were not many developments lately. The inhibition of Rho kinase lowers the intraocular pressure by increasing the outflow through the trabecular meshwork. Increased blood flow to the optic nerve and...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Melatonin effects on Plasmodium life cycle: new avenues for therapeutic approach.
Authors: Srinivasan V, Ahmad AH, Mohamed M, Zakaria R Abstract Malaria remains a global health problem affecting more than 515 million people all over the world including Malaysia. It is on the rise, even within unknown regions that previous to this were free of malaria. Although malaria eradication programs carried out by vector control programs are still effective, anti-malarial drugs are also used extensively for curtailing this disease. But resistance to the use of anti-malarial drugs is also increasing on a daily basis. With an increased understanding of mechanisms that cause growth, differentiation a...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Management of type-1 and type-2 diabetes by insulin injections in diabetology clinics - a scientific research review.
Authors: Aziz KM Abstract Better control of the diabetic metabolic state will prevent the diabetes complications. However in current clinical practice, it is sometimes difficult to achieve this goal. Additionally, physicians find themselves in an equivocal position to initiate insulin therapy, its selection, combining with Oral agents and further management. The current article was written to focus on diabetes pathogenesis at molecular level, its classification and management by insulin injections. Knowledge of basic biochemistry, pharmacology with kinetics of Insulin is essential for diabetes management. ...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Perspectives of new therapies for endometriosis.
Authors: Garmendia JV, De Sanctis JB Abstract Endometriosis is an inflammatory disease characterized by the presence of endometrial glandular epithelial and stromal cells growing in the extra-uterine environment. The disease affects: ovarian function, oocyte quality, embryo development and implantation, and uterine function resulting in infertility or spontaneous pregnancy loss. Even though the world's prevalence is above 10 %, an effective treatment has not yet been found. New pharmacological approaches have been designed and patented that could serve as future therapies for this disease. PMID: 22...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Recent patents and developments in glaucoma biomarkers.
Authors: Colligris B, Crooke A, Gasull X, Escribano J, Herrero-Vanrell R, Benitez-del-Castillo JM, García-Feijoo J, Pintor J Abstract Glaucoma is an eye condition mainly developed from an excessive intraocular pressure. The condition tends to be inherited and may not show up until later in life. The increased pressure, can damage the optic nerve, provoking loss of vision. Without treatment, glaucoma can cause blindness within a few years; consequently glaucoma has to be diagnosed before long-term visual loss occurs. If it is diagnosed and treated early, the disease can be controlled. Usually, the patient ...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

The hypothalamic-neurohypophyseal system: current and future treatment of vasopressin and oxytocyn related disorders.
Authors: Calabrò RS, Italiano D, Ferrara D, Mondello S, Conti-Nibali V, Salviera C, Bramanti P Abstract The hypothalamus and posterior pituitary form a complex neurohumoral system playing a key role in maintaining body fluid homeostasis and reproductive function. We review the pathophysiology mechanisms of posterior pituitary hormones and their implications, beyond water balance and delivery, in social functioning, pair bonding and affiliative behavior. Actual and future treatments for neurohypophysis related disorders are also discussed, particularly focusing on the development of new therapeutic compoun...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Role of thrombin activatable fibrinolysis inhibitor in endocrine and cardiovascular disorders: an update.
Authors: Akinci B Abstract Thrombin activatable fibrinolysis inhibitor (TAFI) is a zymogene that potently inhibits fibrinolysis through the removal of the carboxy-terminal lysine and arginine residues from partially degraded fibrin polymers. In addition, TAFI has a suppressor effect on conversion of inactive plasminogen to plasmin. Since impaired fibrinolysis is a very well established risk factor for cardiovascular morbidity and mortality, understanding the role of TAFI in cardiovascular disorders, insulin resistance, diabetes and other endocrine problems may hold promise for improving management of these...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Therapeutic potential of natural products in Parkinson's disease.
Authors: Mythri RB, Harish G, Bharath MM Abstract The central objective in treating patients with Parkinson's disease (PD) is two-fold (i) to increase the striatal dopamine content and (ii) to prevent further degeneration of the surviving dopaminergic neurons in the substantia nigra region of the ventral midbrain. Most of the current PD drugs contribute to the former and provide symptomatic relief. Although compounds such as Levodopa (L-DOPA) improve the striatal dopamine content, their long-term usage is associated with progressive decrease in drug response, motor fluctuations, dyskinesias and drug-induce...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

HMGB-1 as a target for inflammation controlling.
Authors: Nogueira-Machado JA, de Oliveira Volpe CM Abstract In the present study, we evaluated recent patents that describe products or methods able to down-regulate the pro-inflammatory action of HMGB-1, also called as amphoterin. High Mobility Group Box-1 (HMGB-1) has been implicated in the pathogenesis of inflammatory diseases. HMGB-1 has been proposed to be a crucial mediator in the pathogenesis of many diseases including sepsis, arthritis, cancer, autoimmunity diseases and diabetes. It has been suggested that HMGB-1 itself can signal through RAGEs (receptor for advanced glycation end products) and thr...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Effect of electromagnetic field on the polymerization of microtubules extracted from rat brain.
Authors: Taghi M, Gholamhosein R, Saeed RZ Abstract Microtubules (MTs) are ubiquitous eukaryotic proteinaceous filaments showing a hollow cylindrical structure. MTs are composed of α-β-tubulin heterodimers arranged in linear protofilaments. MTs have a significant electric dipolar moment along their axes, which makes them capable of being aligned parallel to the applied electromagnetic field direction. Tubulin heterodimers were purified from rat brains. MTs were obtained by polymerization in vitro. Samples of microtubules adsorbed under and without electromagnetic fields with 500 Hz frequency. Our results...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Anti-allergic potential of herbs and herbal natural products - activities and patents.
Authors: Cota BB, Bertollo CM, de Oliveira DM Abstract The increase of allergic diseases has accompanied the global population growth and the major challenge is to reduce morbidity. The currently available treatments present limitations regarding efficacy and safety. Hence, patients with chronic allergic conditions seek alternatives to achieve better control of symptoms. Many natural products have been identified as potential anti-allergic agents. In addition, plant formulations have demonstrated, in general, to be safe in clinical trials and demonstrate additional effects along with Western medicines such...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Metabolic syndrome, its pathophysiology and the role of melatonin.
Authors: Srinivasan V, Ohta Y, Espino J, Pariente JA, Rodriguez AB, Mohamed M, Zakaria R Abstract Metabolic syndrome (MetS) is characterised by symptoms of obesity, insulin resistance, hypertension, dyslipidemia and diabetes mellitus. The pathophysiological mechanisms involved in MetS are complex and involved dysregulation of many biochemical and physiological regulatory mechanisms of the body. Elevated levels of low density lipoproteins like VLDL, and LDL with reduction of HDL seen in patients with MetS contribute to atherogenic dyslipedemia. Melatonin has been suggested to be effective in improving MetS ...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research